000			01994 a2200517 4500
005			20250515042235.0
264		0	_c20061228
008			200612s 0 0 eng d
022			_a1527-4160
024	7		_a10.1097/00131746-200609000-00006 _2doi
040			_aNLM _beng _cNLM
100	1		_aPreskorn, Sheldon H
245	0	0	_aClinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II. _h[electronic resource]
260			_bJournal of psychiatric practice _cSep 2006
300			_a312-6 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAnti-HIV Agents _xadverse effects
650	0	4	_aAntidepressive Agents _xadverse effects
650	0	4	_aAntiparkinson Agents _xadverse effects
650	0	4	_aApomorphine _xadverse effects
650	0	4	_aAtazanavir Sulfate
650	0	4	_aAzabicyclo Compounds
650	0	4	_aCarbamates _xtherapeutic use
650	0	4	_aCentral Nervous System Agents _xadverse effects
650	0	4	_aCytochrome P-450 Enzyme System _xmetabolism
650	0	4	_aDrug Approval _xlegislation & jurisprudence
650	0	4	_aDrug Interactions
650	0	4	_aDuloxetine Hydrochloride
650	0	4	_aFurans
650	0	4	_aHumans
650	0	4	_aHypnotics and Sedatives _xadverse effects
650	0	4	_aIndenes _xadverse effects
650	0	4	_aLong QT Syndrome _xchemically induced
650	0	4	_aMental Disorders _xdrug therapy
650	0	4	_aOligopeptides _xadverse effects
650	0	4	_aOrganophosphates _xtherapeutic use
650	0	4	_aPiperazines _xadverse effects
650	0	4	_aPsychopharmacology _xmethods
650	0	4	_aPyridines _xadverse effects
650	0	4	_aSulfonamides _xtherapeutic use
650	0	4	_aThiophenes _xadverse effects
700	1		_aBorges-Gonzalez, Silvana
700	1		_aFlockhart, David
773	0		_tJournal of psychiatric practice _gvol. 12 _gno. 5 _gp. 312-6
856	4	0	_uhttps://doi.org/10.1097/00131746-200609000-00006 _zAvailable from publisher's website
999			_c16576751 _d16576751